Ermond van Beek

As a scientist Ermond van Beek has an extensive experience in the executing of in-vivo experiments and animal testing with a focus on Near Infrared Imaging. In 2011, while conducting contract research for Coretag, it was Van Beek who discovered the necrosis-binding properties of cyanines. This discovery laid the groundwork for the development of Coretag’s patented “Necrosis Targeting Platform Technology.” Over the past decades Van Beek has contributed to 45 different scientific publications focusing on imaging and necrosis targeting. After a 21-year career at LUMC in Leiden, Netherlands, Van Beek joined Coretag in 2016 as the head of pre-clinical development. In the coming years Van Beek continues to conduct pre-clinical research, aiming to contribute to the development groundbreaking new applications for both the imaging and treatment of cancer.